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ABSTRACT
Background
Hepatitis C is a common infection among injecting
drug users and has important implications for general
practice. Although several clinical guidelines
concerning the infection have been published, their
effectiveness has yet to be tested.
Aim
To assess the effectiveness of a general practice-
based complex intervention to support the
implementation of clinical guidelines for hepatitis C
management among current or former drug users
attending general practice.
Design of study
Cluster randomised controlled trial.
Setting
General practices in the Eastern Regional Health
Authority area of Ireland.
Method
Twenty-six practices were randomly allocated within
strata to receive the intervention under study or to
provide care as usual for a period of 6 months. There
was screening for patients attending general practice
for methadone maintenance treatment for hepatitis C
and referral of anti-HCV antibody positive patients to a
specialist hepatology department for assessment.
Results
At study completion, patients in the intervention group
were significantly more likely to have been screened for
hepatitis C than those in the control group, odds ratio
adjusted for clustering 3.76 (95% confidence interval
[CI] = 1.3 to 11.3) and this association remained
significant after adjusting for other potentially
confounding variables, using multiple logistic
regression, with the odds ratio adjusted for clustering
4.53 (95% CI = 1.39 to 14.78). Although anti-HCV
antibody positive patients in the intervention group
were more likely to have been referred to a hepatology
clinic, this was not statistically significant (P = 0.06).
Conclusion
General practice has an important role in the care of
people at risk of hepatitis C and when appropriately
supported can effectively implement current best
practice.
keywords
clinical trial; cluster analysis; family practice;
guidelines; hepatitis C; randomised controlled trial;
screening.
INTRODUCTION
Hepatitis C infection is a common infection
worldwide.1 In the UK, injecting drugs is a risk factor
in the majority of infections2 and in Ireland, 62–81%
of injecting drug users have been reported to test
positive for hepatitis C.3,5
The high prevalence of hepatitis C among this
patient group has clear implications for general
practice, whose role in caring for current or former
injecting drug users in Ireland, the UK and other EU
countries is established.6,8 Specifically, its potential
role in preventing new infections through engaging
patients in harm reduction interventions, screening
patients at risk of infection and providing diagnostic
and therapeutic interventions to those who test
positive has been recently highlighted.9,10
However, ensuring comprehensive and effective
hepatitis C screening and care is a challenge for
general practice in Ireland. A recent audit of blood
borne virus care among current or former drug users
attending general practice for treatment in the
greater Dublin area, reported 34% had been
screened for hepatitis C infection in general
practice.4
In recent years, several clinical guidelines on
hepatitis C care have been published.11,14 At the time
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of this study, while the effectiveness of clinical
guidelines in improving management of hepatitis C in
general practice had not been demonstrated, an
emerging consensus existed that successful
guideline implementation in general practice required
adopting multi-faceted interventions addressing
potential barriers to change.15,16
We aimed to assess the effectiveness of a complex
intervention, involving the dissemination of clinical
guidelines and the provision of an accompanying
implementation programme targeting multiple
barriers to change, to improve hepatitis C care
among current or former drug users attending
general practice for methadone maintenance
treatment, in a cluster randomised controlled trial.
METHOD
Setting and context
Since the introduction of legislation regulating the
prescribing and dispensing of methadone in Ireland, it
is not possible for doctors to prescribe nor for
pharmacists to dispense methadone unless a
patient’s name has been entered on the ‘Central
Methadone Treatment List’, a database of patients on
methadone treatment coordinated by the Department
of Health and Children.20 To prescribe methadone,
GPs are subject to clinical audit and must complete
special training, with GPs providing methadone
treatment for 15 or more patients subject to more
regular audit and advanced training. GPs who
prescribe methadone for less than 15 patients are
referred to as ‘level one GPs,’ and those prescribing
for 15 or more as ‘level two’ GPs. Initiation of
methadone therapy is only permitted by specialist
addiction treatment services or by ‘level two’ GPs.20
This system is analogous to the GPs with a special
interest model currently operating in the UK.6
Intervention
Clinical guidelines for the management of hepatitis C
were developed by a multidisciplinary expert panel.
Content was derived from scientific evidence where
this was available and from a Delphi-facilitated
consensus development process where it was not
and included: general advice on lifestyle,
immunisation against other hepatotrophic viruses,
screening for hepatitis C (and other bloodborne
viruses), subsequent diagnosis (including
polymerase chain reaction (PCR) testing and
addiction–related care) and specialist assessment.
The development and content of these guidelines
have been reported separately.21
The intervention was developed subsequent to a
series of semi-structured interviews with a sample of
GPs currently involved in providing methadone
maintenance treatment in the region. It consisted of
disseminating the clinical guidelines practice based
educational sessions that covered guidelines’
content and their implementation and nursing
support.22 Nursing support consisted of a liaison
nurse who was responsible for discussing the
content of the guidelines with all practice staff (both
clinical and non-clinical), identifying the needs of
each practice with regard to effective implementation
of the guidelines, providing clinical and
administrative support to individual practices,
training practice nursing and other staff, providing
advice and support to practice nurses and GPs,
encouraging the uptake of the clinical guidelines and
liaising with specialist hepatology and addiction
treatment services. The liaison nurse held a 1.0
whole–time equivalent post for the duration of the
study.
Consultations held by the liaison nurse with
individual patients were consistent with the clinical
guidelines’ content and included counselling and
screening patients for infection with hepatitis C and
other bloodborne viruses, immunising patients
against other hepatotrophic viruses, counselling
patients on the implications of testing positive for
hepatitis C on initial screening and facilitating
subsequent investigations among those identified as
hepatitis C-positive. GPs in participating practices
remained clinically responsible for individual patient
care throughout the intervention period.
The intervention lasted for 6 months. This was felt
to be of sufficient duration for significant outcomes
to be detected and sufficiently short to avoid
contamination by other initiatives.
Study outcomes
Two outcomes, screening at risk populations for
hepatitis C infection and antiviral therapy were
considered as primary outcomes for the study, as
both were associated with improved clinical
outcomes and are cost-effective.23–28 However, at the
time of this study, it was not possible, nor did the
clinical guidelines recommend, that antiviral therapy
be initiated in general practice. For these reasons,
How this fits in
Injecting drugs is the main route of transmission of the hepatitis C virus in the
UK and Ireland. This has important implications for general practice whose role
in the treatment of people who have injected drugs is established. A cluster
randomised controlled trial of a complex intervention to implement recently
published clinical guidelines, designed after consultation with local GPs,
demonstrated that the dissemination of clinical guidelines plus clinical and
educational support resulted in measurable improvements in screening for
hepatitis C infection and several other aspects of patient care.
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the primary outcomes were the proportion of current
or former drug users attending general practice for
methadone treatment who had been screened for
hepatitis C infection and the proportion of anti-
hepatitis C antibody positive patients who had been
referred to a specialist hepatology department for
assessment regarding treatment.
Sample size considerations
Recent data on blood-borne virus care among drug
users attending general practice for methadone
maintenance treatment in the ERHA area estimated
that only 34% of all patients that had been screened
for hepatitis C infection in general practice and only
35% of those known to be hepatitis C-positive had
been referred to a hepatologist for assessment.4,29
To detect a twofold increase in levels of hepatitis C
screening and a twofold increase in the proportion of
hepatitis C-positive patients who had been referred
to a specialist for assessment, it was estimated that
data on 156 and 201 patients, respectively, would be
needed. This assumed a power of 80%, a
confidence level (CI) of 95%, hepatitis C prevalence
of 73%4 and an intracluster correlation coefficient
(ICC) of 0.15 (which in the absence of data
estimating the ICC for hepatitis C care, was felt to be
a conservative upper limit).30
To maximise the number of practices eligible for
recruitment, thus minimising the design effect, and to
ensure efficient use of resources in delivering the
complex intervention, a pragmatic decision to adopt
a cluster size of eight patients per practice was
selected. Hence, data was required on each of the
eight patients attending 27 practices.
Recruitment and allocation of practices
Practices were eligible for inclusion in the study if one
of the GP principals was registered to prescribe
methadone and at least eight patients were currently
being prescribed methadone in the practice and
excluded if one of the GP principals had been
involved in developing or reviewing the guidelines. In
addition, practices where more than one GP was
registered to prescribe methadone were considered
as one practice for the purpose of the study, leaving
a total of 47 practices eligible to participate (Figure 1).
A stratified random sampling technique (based on
level of training of the GP principals and area of
practice) was used to select 27 practices out of the 47
eligible, of which 26 practices (prescribing methadone
to 538 patients) agreed to participate in the study.
To ensure comparability between intervention and
control groups, practices were stratified according to
the level of training of the GP principals in providing
addiction care and according to whether their
practice employed a practice nurse. Following
stratification, a restricted randomisation procedure
was carried out, whereby practices in each stratum
were assigned a number and random numbers used
to select practices that would comprise the control
group, with the remainder being allocated to the
intervention group.
Of the 26 practices randomised, 25 recruited
patients for the trial (13 in the intervention group and 12
in the control group). One practice withdrew after
randomisation from the control group, owing to
practice restructuring.
A staggered intervention design was adopted,
whereby practices randomised to the intervention
arm of the trial were provided with the complex
intervention for the duration of the study period, with
the practices randomised to the control arm of the
trial providing usual care to patients for the duration
of the study and provided with the complex
intervention thereafter.
Recruitment of patients
The systematic and consistent random sampling of
patients in the participating practices was not
guaranteed and hence, a standardised non-probability
sampling framework was used to identify eight
patients from each practice on whom data would be
collected for the purpose of the study. GPs in
participating practices provided consecutive patients
requesting a prescription for methadone with written
information on the project and subsequently asked
each patient to consent to allow a member of the
research team have access to their medical records.
Data collection
The clinical record of each consenting patient was
Total number of GPs
prescribing methadone
n = 139
Practices eligible
for trial
n = 47
Practices agreed to
 participate in trial
n = 26
Practices invited to 
participate
n = 27
GPs working in the 
same practice
n = 30,
GPs involved in 
guideline
development/
review n = 10,
GPs prescribing
methadone for 
fewer than 8
patients n = 52
Stratification based 
on level of training
and region
Practice declined to 
participate n = 1
Figure 1. Recruitment
of practices for the trial.
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examined on-site by one of the research team, who
had no input into clinical care or into the
implementation of guidelines. The accuracy of data
extraction was checked by the principal investigator
who examined 10% of the records at baseline and on
study completion.
Data were collected at time zero and after
6 months and included the primary outcome
measures (evidence of screening for hepatitis C in
the practice and of referral of hepatitis C-positive
patients to a hepatology department), demographic
and drug using characteristics and all aspects of
clinical care covered by the clinical guidelines
including: general aspects of care, screening for
other blood borne viruses, immunisation against
other hepatotrophic viruses, and subsequent
management of hepatitis C-positive patients.
At the time of the study, GPs were required to
monitor compliance and use of illicit drugs among
patients on methadone maintenance treatment by
testing urine samples for methadone, morphine,
amphetamine, cocaine and benzodiazepine
metabolites at intervals of no more than a week. The
results of urinalysis testing for each patient during
the previous 3 months were reviewed and the
number of samples containing metabolites of non-
prescribed illicit drugs was recorded.
Evidence of patients being screened for blood
borne virus infections was based on the presence of
results of anti-HCV antibody, anti-HIV antibody,
HBSag or anti-HBc antibody testing in individual
patient records held by the practice. At the time of
the study, testing for hepatitis C antibodies (anti-HCV
antibody) was with a third generation enzyme linked
immunoadsorbent assay (EIA), with positive assays
confirmed by radioimmunoblot (RIBA) assay; testing
for HIV antibodies (anti-HIV) involved two EIAs, with
positive assays confirmed by Western Blot assay and
testing for both HBV surface antigen (HBSag) and
HBV core antibody (anti-HBc) was with an EIA.
Data analysis
Analysis of primary outcomes was by intention to
treat and was performed in three steps with the least
conservative described first.
The proportions of patients in intervention and
control populations who had been screened for anti-
hepatitis C antibody by their GP and if positive, to
have been referred to or attended a specialist
hepatology clinic for assessment were compared
using the Mantel-Haenszel pooled odds ratio.
Using the ‘svyset’ series of commands in STATA
version 6.0, logistic regression analysis (using
‘svylogit’) was performed to allow for the potential
bias introduced by the clustered design. In this
analysis, the practice variables used in the stratified
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Characteristic Intervention Control
Practice factors at baseline (n = 13) (n = 12)
Area of practice
A 5 7
B 7 3
C 1 2
Single practitioner
Yes 6 6
No 7 6
Number of patients on methadone
<15 6 5
≥15 7 7
Type of clinical record
Paper 3 4
Electronic 1 2
Combination 9 6
Preferred hepatology unit for referral
D 5 7
E 1 2
F 4 2
G 3 1
Patient factors at baseline (n = 104) (n = 92)
Mean age (years) 33.1 31.8
Mean time attending practice 33.2 27.8
for methadone treatment (months)
Mean age of first using drugs (years) 17.1 16.9
Mean age of first injecting (years) 20.0 19.9
Male, n (%) 84/104 (81) 58/92 (63)
Provided urine sample containing metabolite 57/104 (55) 42/92 (46)
of any illicit drug in the previous 3 months (%)
Provided urine sample containing 35/104 (34) 25/92 (27)
opiate metabolite in the previous 3 months (%)
Screened for hepatitis C by GP (%) 35/104 (34) 24/92 (26)
Referral initiated if HCV antibody positive (%) 20/67 (30) 11/37 (30)
Attended specialist clinic if HCV antibody positive (%) 16/67 (24) 8/37 (22)
Table 2. Baseline comparison of intervention and control
groups at cluster and individual levels.
Participating All GPs
Variable Characteristic GPs (n = 25) (n = 139)
Patients on <15 11 95
methadone >15 14 44
Level of training
Basic (‘level one’) 18 110
Advanced (‘level two’) 7 29
Health board area
A 12 6
B 10 45
C 3 26
Table 1. Participating GPs compared
with all GPs providing methadone
maintenance treatment in the region.
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randomisation process, namely the presence of a
practice nurse and the level of training in providing
addiction related care of the GP were included as
‘strata’, practices were included as the primary
sampling units (‘PSUs’) and individual patients were
assigned a weighting based on the inverse
probability of that patient being selected from all
patients attending that practice (‘pweight’).
To allow for potentially confounding variables that
had not been considered in this stratification
process, further logistic regression analysis was
performed on the clustered dataset.
We considered P values of <0.05 and of <0.01 to
imply statistical significance in the case of primary
and secondary outcomes respectively.
RESULTS
Baseline data
The sample of GPs participating in the study was
representative of all GPs in the region prescribing
methadone in terms of the level of training in
providing addiction care and the health board area in
which their practice was located, but had a higher
proportion of GPs providing methadone
maintenance treatment to 15 or more patients (Table
1). Compared to a national census of GPs, the
sample had a lower proportion of female GPs, a
higher proportion of GPs with personal GMS lists
and a higher proportion of GPs working in a practice
that employed a practice nurse.31,32
There were no differences between the
‘intervention’ and ‘control’ practices for a range of
characteristics, including: health board area of
practice, type of clinical record used, number of
patients on methadone maintenance treatment,
and whether the practice consisted of a single GP
(Table 2).
Patients attending ‘intervention’ and ‘control’
practices were comparable in terms of demography,
drug using history, recent illicit drug use, screening
for hepatitis C and referral to and attendance at a
specialist unit for assessment if HCV antibody
positive. The ‘intervention’ group of patients
contained a significantly higher proportion of males
compared to the control (Table 2).
Participant flow and follow up
Figure 2 illustrates the flow and follow up of patients
through the trial. Although all practices had at least
eight patients on methadone maintenance treatment
at recruitment, at the time baseline data were
collected, one practice had only six and two
practices had only seven patients on methadone
maintenance treatment. Therefore, data were
recorded on 196 patients attending 25 practices,
with 104 attending ‘intervention’ and 92 attending
‘control’ practices.
Although 11 patients were no longer receiving
methadone maintenance treatment from their GP at
follow up (6% of total), all 11 were still registered as
continuing to attend the practice for general medical
care and in this regard, were not considered as
losses to follow up. For this reason and because
analysis of outcome data is presented on an
intention to treat basis, these cases were included in
subsequent analyses.
There were no significant differences between
groups for the proportions of patients no longer being
prescribed methadone, who had stopped methadone
treatment or who were being prescribed methadone
by another agency. Five of the 104 patients in the
‘intervention’ arm of the trial were no longer receiving
methadone maintenance treatment from their GP at
trial completion. Of these, two were no longer on
methadone treatment and three were being
prescribed methadone by another agency. Six of the
92 patients in the ‘control’ arm of the trial were no
longer receiving methadone maintenance treatment
from their GP at trial completion. Of these, four were
no longer on methadone treatment and two were
being prescribed methadone by another agency.
Practices randomised to
 ‘intervention’ arm
n = 13
Patients from whom consent to 
allow access to records was
sought n = 106a
Outcome patient
data
n = 104
Baseline patient
data n = 104a,
received complex intervention
No longer on methadone n = 2
Receiving methadone from 
another agency n = 2
Practices randomised to
 ‘control’ arm
n = 12
Patients from whom consent to 
allow access to records was
sought n = 94a
Outcome patient
data
n = 92
Baseline patient
data n = 92a,
received usual care
No longer on methadone n = 4
Receiving methadone from 
another agency n = 2
Practices agreed to 
participate in trial
n = 26
Practice
withdrawal
n = 1
Baseline data collection
Figure 2. Consort
diagram representing
follow up of patients
through the trial.
aAlthough all practices had at least eight patients on methadone treatment at
recruitment, at baseline data collection, two practices had only seven patients and one
practice had only six patients.
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No deaths were reported in either intervention or
control populations during the study period.
Primary outcomes
At study completion, patients in the intervention
group were significantly more likely to have been
screened for hepatitis C in general practice than
those in the control group and if anti-HCV antibody
positive were significantly more likely to have been
referred to a hepatology clinic for assessment.
However, after correction for clustering, only the
former remained statistically significant (Table 3).
Further logistic regression analysis was performed
in which potentially confounding variables not
considered in the stratification process, were entered
into a logistic regression equation against whether
patients had been screened for hepatitis C. These
variables included: if the practice had one doctor, had
less than 15 patients on methadone maintenance, the
health board area in which the practice was located,
the type of clinical records used in the practice, patient
gender and the preferred hepatology unit for referral.
On this analysis, being in the intervention group was
the only variable significantly associated with having
been screened for hepatitis C in general practice,
odds ratio = 4.53; 95% CI = 1.39 to 14.78; P = 0.02.
The intracluster correlation coefficients (95% CI)
for the primary outcomes were 0.09 (0.00 to 0.33) in
respect of screening for hepatitis C in general
practice and 0.13 (0.00 to 0.50) in respect of referral
of anti-HCV antibody positive patients to a
hepatology unit, findings consistent with the ICC
used to determine sample size.
Secondary outcomes
After correction for clustering, patients in the
intervention group were significantly less likely to
have provided a urine sample that contained a
metabolite of any illicit drug. In addition, anti-HCV
antibody positive patients in the intervention group
were significantly more likely to have been given
advice on reducing alcohol consumption (Table 4).
Although not to statistically significant levels,
greater proportions of patients in the intervention
group had been screened for hepatitis B, had been
immunised against hepatitis A and B and if anti-HCV
antibody positive, greater proportions of patients in
the intervention group had been tested for HCV-
RNA, had attended a hepatology clinic, had a liver
biopsy performed and had antiviral therapy initiated
(Table 4).
DISCUSSION
Summary of main findings
The cluster randomised controlled trial demonstrated
that a complex intervention consisting of the
dissemination of recently published clinical
guidelines, a liaison nurse to assist practices with
clinical care of patients and patient education, and
educational support tailored to the needs of
individual practices resulted in a significant increase
in hepatitis C screening among current or former
injecting drug users attending general practice. We
were unable to demonstrate an increase in referral of
anti-HCV antibody positive patients for hepatology
assessment.
The intervention was also associated with a
significant increase in the number of anti-HCV
antibody positive patients who received advice on
reducing alcohol and a significant decrease in the
number of patients who provided their GP with a
urine sample containing metabolites of illicit drugs.
Strengths and limitations of the study
Although the study predated its publication, the
design and conduct of the trial was in accordance
with the recommendations contained in a revised
CONSORT statement concerning cluster
randomised trials.32
In order to provide comparability between
intervention and control groups, stratification of GPs
occurred prior to randomisation. With a relatively
small number of GPs eligible for randomisation, it
was felt unrestricted allocation or complete
randomisation could introduce imbalance between
groups for key practice characteristics.
Potential bias was introduced by data being
extracted from clinical records. As chart abstraction
853
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Evidence of primary Adjusted
outcome in clinical Intervention Control Odds ratioa odds ratiob ICC
record n (%) n (%) (95% CI) (95% CI) P-value (95% CI)
Screened for hepatitis C by GP 51/104 25/92 2.58 3.76 0.02 0.09
(49) (27) (1.4-4.7) (1.3-11.3) (0.0-0.3)
Referral initiated if HCV 44/73 13/41 3.27 3.15 0.06 0.13
antibody positive (60) (32) (1.5-7.3) (0.9-10.7) (0.0-0.5)
aPatient level analysis. bCluster level analysis. ICC = intracluster correlation coefficient.
Table 3. Comparison of primary outcome measures between intervention and
control populations at study completion analysed at patient and cluster level.
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has recently been shown to underestimate quality of
care for common outpatient general medical
conditions when compared with standardised-patient
reports,34 it is possible the findings may have under-
reported the true process of care delivered. However,
the principal investigator reviewed a 10% random
sample of clinical records from which the researcher
had collected data and no inter-observer variation was
noted. In addition, with data on both intervention and
control populations being collected in an identical
manner by the same researcher, data on both
populations were subject to the same potential bias.
As a result, it was to be expected that no material
differences between patients attending intervention
and control practices would be identified at baseline.
While both populations were comparable, in
particular for the primary outcomes, the intervention
group contained a higher proportion of males,
thereby compromising internal validity. However, the
inclusion of gender as a factor in subsequent
multivariate logistic regression analysis is likely to
have minimised any potential resulting bias.
External validity may have been compromised by
selection bias at practice and individual patient level.
Practices with fewer than eight patients on methadone
at recruitment and practices where one of the GP
principals was involved in developing or reviewing the
clinical guidelines were excluded from this study. As a
result, it is likely patients attending practices with
limited experience or practices with extensive
experience of caring for current or former drug users
were not represented in this study. It is possible that
the exclusion of less experienced GPs may have led to
an underestimate of the effect of the intervention.
Evidence of secondary Intervention Control Odds ratio Adjusted odds ratio ICC
outcome in clinical record n (%) n (%) (95% CI)a (95% CI)b P-value (95% CI)
Among study population n = 104 n = 92
Mortalities 0 (0) 0 (0) NA NA NA NA
Still prescribed methadone by GP 99 86 1.38 2.26 0.16 0
(95) (94) (0.41–4.69) (0.70–7.29) (0–0.30)
Provided urine sample containing 24 50 0.25 0.16 0.003 0.18
metabolite of any illicit drug (23) (54) (0.14–0.47) (0.05–0.50) (0–0.61)
Provided urine sample containing 8 23 0.25 0.26 0.07 0.10
opiate metabolite (8) (25) (0.11–0.59) (0.06–1.15) (0–0.36)
Tested for anti-HIV antibody by GP 42 31 1.33 1.54 0.28 0.00
(40) (34) (0.74–2.39) (0.68–3.50) (0–0.3)
Tested for anti-HBc antibody or 51 24 2.73 3.87 0.02 0.10
HBSag by GP (49) (26) (1.49–4.99) (1.28–11.66) (0–0.36)
At least one hepatitis B vaccine 73 38 3.35 4.66 0.02 0.15
administered (70) (41) (1.85–6.04) (1.33–16.32) (0–0.52)
Complete course of hepatitis 37 17 2.44 3.07 0.06 0.06
B vaccine administered (36) (19) (1.26–4.72) (0.94–10.01) (0–0.25)
At least one HAV vaccine 40 11 4.60 6.22 0.02 0.16
administered (39) (12) (2.19–9.68) (1.36–28.52) (0–0.55)
Complete course of HAV 11 2 5.32 4.86 0.09 0.05
vaccine administered (11) (2) (1.15–24.69) (0.76–31.10) (0–0.19)
Among patients who were
anti-HCV positive n = 73 n = 41
Advised on reducing alcohol 49 6 11.91 12.27 0.003 0.41
(67) (15) (4.41–32.19) (2.70–55.76) (0–1.11)
Tested for the presence of 41 9 4.56 4.53 0.05 0.20
HCV-RNA in serum (56) (22) (1.90–10.90) (1.02–20.14) (0–0.67)
Attended hepatology clinic 37 9 3.65 5.13 0.04 0.14
(51) (22) (1.5–8.7) (1.1–23.1) (0–0.5)
Liver biopsy performed 18 3 4.15 5.07 0.05 0.08
(25) (7) (1.14–15.06) (1.01–25.34) (0–0.32)
Antiviral therapy initiated 5 1 2.94 4.72 0.20 0.00
(7) (3) (0.33–26.08) (0.42–53.23) (0–0.5)
aPatient level analysis. bCluster level analysis.
Table 4. Comparison of secondary outcome measured between intervention and
control populations at study completion analysed at patient and cluster level.
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Nonetheless the sample of GPs was representative of
all GPs in the region prescribing methadone at the
time of the study in terms of the level of training in
providing addiction related care and the health board
area in which their practice was located.
Furthermore, while the study was limited to only
one of Ireland’s eight health regions, the most
recently published data estimate that 85% of all
people attending addiction treatment services in
Ireland do so in this area.19
The systematic random sampling of patients was
not feasible because of considerable variation in the
maintenance of disease registers among the sample
of participating practices. To minimise inter practice
variations in sampling, therefore, a standardised non-
probability sampling framework was used in which
participating GPs sought consent from eight
consecutive patients attending their practice for
methadone maintenance treatment to allow his or
her records be reviewed by a member of the research
team. As GPs knew to which arm of the study they
had been assigned and knew the patients who had
consented to a member of the research team have
access to their records, this may also have added to
the selection bias.
Despite the potential bias introduced by these
factors, the sample of patients on whom data is
presented is similar in demographic and drug using
characteristics to other larger samples of current or
former injecting drug users in Ireland.35,36
Comparison with existing literature
The role of general practice in the primary and
secondary prevention of hepatitis C-related illness
has recently been highlighted.10 The clinical
guidelines whose content formed the basis of this
trial offered clear advice in this regard for GPs
involved in the care of current or former injecting
drug users and included harm reduction,
immunisation against other hepatotrophic viruses
and screening for hepatitis C (and other bloodborne
viruses). In addition, for those patients who test anti-
HCV antibody positive, they recommended lifestyle
advice, diagnostic tests and referral for specialist
assessment. Considerable overlap exists between
these and other recent publications.11,14
By demonstrating a significant increase in
screening for hepatitis C, the trial was in part
successful. It is perhaps worth reflecting that at study
completion, 25 people in the control group (compared
to 24 at baseline) had been screened for hepatitis C.
This finding is consistent with previous studies from
Ireland, indicates a need for interventions that
improve access to and uptake of screening for
hepatitis C and supports the view that effective
implementation of clinical guidelines requires
adopting multi-faceted complex interventions that
target individual barriers to change.15,16
While it is inappropriate to attempt to identify the
elements of the complex intervention that were most
important, some insights in this regard may be gained
by our qualitative interviews with a representative
sample of GPs to inform the design of the complex
intervention conducted in advance of its introduction.
These interviews highlighted the importance of clinical
and organisational support to the successful
implementation of the clinical guidelines and the
potential contribution of a liaison nurse in this respect.22
These interviews also indicated the resource
implications for primary care of effective guidelines
implementation as lack of resources at practice level
and lack of time were among the main barriers to
effective implementation of the clinical guidelines. In
the complex intervention, screening for hepatitis C
was accompanied by information, advice, consent
and support before and after testing, an approach
whose importance has recently been highlighted.37
Clearly while this approach should be incorporated in
any subsequent intervention designed to improve
screening for hepatitis C in primary care, it is likely to
have considerable resource implications for primary
care. It would appear that the resource implications
of improving screening for hepatitis C, allied to the
findings of this trial, justify the provision of such
supports.
The trial did not demonstrate a significant increase
in referral of anti-HCV antibody patients for
assessment. This may be explained by the duration
of the trial being too short as referring a patient for
assessment represents a later stage in the care
pathway. Alternatively, it may be explained by this
outcome being subject to a larger clustering effect,
(ICC = 0.13, compared to 0.09 in the case of
screening for hepatitis C).
The finding that patients in the intervention group
were less likely to provide a urine sample containing
an illicit drug metabolite was unexpected, but
welcome. This data had been collected to determine
the extent to which screening and treating patients
for bloodborne viruses would lead to relapse to illicit
drug use and while the findings do not establish a
causal link between the complex intervention and a
reduction in illicit drug use, an association clearly
exists. Once again, the additional time and care
provided to patients in the intervention group by the
liaison nurse should be considered as important in
contributing to this outcome.
Implications for clinical practice and future
research
Hepatitis C — an Action Plan for England, has
outlined the need for ‘intensified action … to prevent
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new infections, to reduce the level of undiagnosed
infection and to provide better more coordinated
pathways of care for people with hepatitis C, from
their initial diagnosis to specialist care and
treatment, if appropriate’.38 While providing care that
is informed by scientific evidence and expert
consensus may be challenging, this study has
demonstrated that when adequately supported by a
complex (educational and clinical) intervention,
general practice has an important role in caring for
people at risk of or infected with hepatitis C,
specifically the primary and secondary prevention of
harm resulting from related illness.
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